BIND Therapeutics Appoints Andrew Hirsch as President and Chief Executive Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BIND Therapeutics (BIND) Appoints Andrew Hirsch as Permanent CEO
June 22, 2015 10:17 AM EDTBIND Therapeutics (Nasdaq: BIND) announced that Andrew Hirsch has been appointed president and chief executive officer of the Company. Mr. Hirsch had been serving in the role on an acting basis since March 2015. Mr. Hirsch has also been elected to BINDs Board of Directors.
After a thorough evaluation of internal and external candidates, the Board is confident that Andrew is the right person to lead the next phase of the Companys growth, said Daniel Lynch, Chairman, BIND Therapeutics Board of Directors. His vision, operational philosophy and experience are ideally suited for the... More
